Topics Molecular Medicine

Molecular Medicine


1.  Role of FoxO1 transcription factor in B-cell malignancies

​Supervisor:  doc. MUDr. Mgr. Marek Mráz, Ph.D.

RG:  Marek Mraz Research Group

Keywords:  CLL, FoxO1, targeted therapy, microenvironment, apoptosis


2.  Regulation of BCR signalling by DNA damage response and P53 protein

​Supervisor:  Mgr. Miroslav Boudny, Ph.D.

​Consultant:  doc. MUDr. Mgr. Marek Mráz, Ph.D.

RG:  Marek Mraz Research Group

Keywords:  BCR signalling, DNA damage response, p53


3.  Development of bioinformatics methods for multi-omics approaches in cancer research

​Supervisor:  Mgr. Vojtěch Bystrý, Ph.D.

​RG:  Bioinformatics Core Facility

Keywords:  bioinformatics, multi-omics, cancer research, genomics, transcriptomics, proteomics


4.  Development of bioinformatics methods for radiogenomics approaches in cancer research 

​Supervisor:  Mgr. Vojtěch Bystrý, Ph.D.

​RG:  Bioinformatics Core Facility

Keywords:  bioinformatics, radiogenomics, cancer research, genomics, radiomics, spatial transcriptomics


5.  Role of transcription factors in onset and progression of B-cell malignancies

​Supervisor:  RNDr. Josef Vecera, Ph.D.

​RG:  Marek Mráz Research Group

Keywords:  CLL, transcription factor, epigenetics, microenvironment


6.  Functions of cyclin-dependent kinase 11 (CDK11) in regulation of gene expression and tumorigenesis

Supervisor:  Mgr. Dalibor Blažek, Ph.D.

​RG: Dalibor Blažek Research Group

Keywords:  CDK11, transcription, mRNA processing, RNA polymerase II, cancer, genomics, proteomics, kinase inhibitors


7.  Characterization of cyclin-dependent kinase 12 (CDK12) substrates and their roles in regulation of transcription and tumorigenesis

​Supervisor:  Mgr. Dalibor Blažek, Ph.D.

​RG: Dalibor Blažek Research Group

Keywords:  CDK12, transcription, mRNA processing, RNA polymerase II, cancer, genomics, proteomics, kinase inhibitors


8.  Characterization of resistance mechanisms to targeted therapy in acute myeloid leukemia and identification of novel therapy opportunities

Supervisor:  Mgr. Michal Šmída, Dr. rer. nat.

​RG: Michal Šmída Research Group

Keywords:  Acute myeloid leukemia (AML), targeted therapy, CRISPR/Cas9 screening, precision medicine, therapy resistance